This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novo Nordisk A/S
Drug Names(s): NN9925
Description: NN9925 is an orally administered GLP-1 compound.
To address the key challenges relating to oral delivery of GLP-1, Novo Nordisk has designed a GLP-1 analogue, which is more resistant to enzymatic degradation. Furthermore, the compound is formulated using Merrion Pharmaceutical's GIPET technology to facilitate GLP-1 absorption from the gut.
Deal Structure: In January 2009, Merrion Pharmaceuticals and Novo Nordisk announced that the companies entered into a Development and License Agreement to develop and commercialise oral formulations of a Novo Nordisk proprietary GLP-1 receptor agonist, using Merrion's proprietary GIPET technology.
Under this license agreement, Merrion will receive up to US$58 million for the first product developed under the agreement to reach the market based on achievement of certain development, regulatory and sales milestones as well as royalties on sales. Novo Nordisk is responsible and will pay for the development and commercialisation of the product candidates. Merrion is responsible for the development and manufacture of the initial clinical batches, with the work overseen by a joint development committee. The agreement also provides Novo Nordisk with the ability to develop additional oral formulations of Novo Nordisk GLP-1 receptor agonist compounds using Merrion's proprietary absorption enhancing GIPET...See full deal structure in Biomedtracker
Partners: Merrion Pharmaceuticals Plc.
Additional information available to subscribers only: